Object It was reported that the liver fibrosis is reduced in patients with chronic liver disease type C after eradication of HCV. Degree of fibrosis was expressed by the classical fibrosis scoring system (F0-F4) at present. However a change of subtle reduction of fibrosis cannot be expressed in its fibrosis score and thus we measured an area of fibrosis and compared detailed change of the fibrosis area in paired liver biopsy.
Introduction
Hepatitis C virus (HCV) often causes chronic hepatitis and liver cirrhosis, and life-long infection is a high risk factor for hepatocellular carcinoma (HCC). It is believed that liver cirrhosis is a definite precancerous lesion and that it could progress to HCC at least in some patients. Appropriate assessment of the degree of hepatic fibrosis in chronic viral hepatitis is important in order to understand the natural history of hepatitis C as well as to predict against the potential development of HCC.
It was generally thought that liver fibrosis was an irreversible reaction and that it never shows improvement, particularly in cases with liver cirrhosis. However, recent studies indicated that liver fibrosis is a reversible process despite the potential progression to liver cirrhosis (1) (2) (3) (4) (5) (6) . Clinically, we have encountered several patients who showed histopathological improvement of liver fibrosis during long-term follow-up after interferon (IFN) therapy for HCV infection. Although histopathological evaluation of liver fibrosis, such as the classical fibrosis staging score system (7) and histological activity index (HAI) score (8) , have been used for the assessment of liver fibrosis, such evaluation is not fully objective and lacks a quantitative aspect. In the classical fibrosis staging score system (staging score), the F4 stage stands for liver cirrhosis. Although liver cirrhosis reflects the histopathological distortion of the lobular architecture and formation of porto-portal (-central) bridging, the density of the fibrous septa has not been assessed quantitatively. Therefore, there is a need for a precise quantitative evaluation of liver fibrosis, especially in liver cirrhosis, using objective criteria. The main purpose of the present study was to provide quantitative evaluation of liver fibrosis by using a digital image analysis system and to determine the extent of fibrosis before and after treatment of chronic liver diseases.
Material and Methods

Subjects
Twenty-five patients (20 men and 5 women; mean age, 55.5 years; range, 29-72 years) with hepatitis C infection, 20 complete response to IFN therapy who showed viral eradication (CR) and 5 non-treated patients with IFN (CT). All patients underwent paired liver biopsies at the first visit to the hospital and at the time of normalization of liver function post-IFN treatment or natural course associated with fluctuation of liver function. Informed consent was obtained from each patient before the first liver biopsy and the second biopsy carried out at patient's request. All specimens were adequate for the determination of the classical fibrosis staging score system (7). All experimental procedures were approved by the human ethics committee of Arita Gastroenterological Hospital.
Histopathological evaluation
For accurate histopathological evaluation, it is important to avoid sampling error and obtain a sufficient number of samples. Liver biopsy was performed using a Bard Biopsy needle and two biopsy specimens, each measuring more than about 15 mm long, were obtained. The area of fibrosis was quantified by using the following procedures. All biopsy specimens were fixed in formalin and then paraffin embedded. Subsequently, 2-4 m-thick sections were prepared for hematoxylin-eosin staining, Azan-Mallory stain and silver impregnation. After the staining, all samples were examined under a microscope by two independent pathologists who were blinded to the clinical data. The fibrosis stage was evaluated by the classical fibrosis staging score system (staging score) (7). Staging was defined as F0 (no fibrosis), F1 (mild fibrosis), F2 (moderate fibrosis), F3 (severe fibrosis), and F4 (cirrhosis).
For ease of handling, we chose the Azan-Mallory stained samples for digital imaging analysis. The full-length biopsy specimen was digitally processed as follows: The digitized captured material was divided into 20 to 40 segments at ×10 magnification using an image analysis system consisting of an Olympus bx50 light microscope (Olympus Optical Co., Tokyo, Japan), a Fuji Film HC-2500 digital camera (Fuji Photo Film Co., Tokyo), Apple computer with Photograb-2500 (Fuji Photo Film Co.) and then the digitized images were combined into one using Adobe Photoshop Ver. 5.02 software (Adobe Systems Inc., San Jose, CA) (Fig. 1A) . Using the same software, we obtained two-toned samples and quantified the whole liver biopsy area of the tissue using NIH image software (version 1.62, http://rsb.info.nih.gov/ nih-image/) (Fig. 1B) . In the Azan-Mallory stained sections, fibrosis appeared as blue-colored tissue. We selected the blue area automatically using Adobe Photoshop Ver. 5.02 software, and quantified the total area of fibrosis in the same manner (Fig. 1C) . The relative area of fibrosis was determined by dividing the fibrosis area by the whole liver biopsy area. The percent change in the relative area of fibrosis between the first and second biopsy specimens was calculated by dividing the relative fibrosis area of the second biopsy by that of the first biopsy specimen.
Statistical analysis
All data were expressed as mean±SEM. Differences between groups were examined for statistical significance using the Student's t-test. A P value less than 0.05 denoted the presence of a statistically significant difference.
Results
Background of patients and histopathological evaluation of the biopsy specimens Table 1 lists the clinical and biochemical background of the patients enrolled in the present study, including those in whom HCV was eliminated by IFN therapy (CR) and patients who did not receive IFN treatment (CT). There were no significant differences in age, sex ratio, serum alanine aminotransferase (ALT) level, and platelet (PLT) between two groups at baseline. Biopsies were taken at entry and at completion of therapy (range, 13-72 months, 37.3±4.0 for patients of the CR group and after 37-84 months, 57.0±7. for those of the CT group).
Evaluation of two biopsy specimens by classical fibrosis staging score system Table 2 lists the staging score, fibrous ratio determined by computed image analysis, and observation period. At the time of the first liver biopsy, 9 cases were classified as stage F4 (36%), 6 as F3 (24%), 1 as F2 (4%), 5 as F1 (20%), and 4 as stage F0 (16%) based on the classical fibrosis staging score. With respect to the CR group, 8 cases were classified as stage F4 (40%), 4 as F3 (20%), 1 as F2 (5%), 5 as F1 (25%), and 2 as stage F0 (10%).
Comparison of the staging score between the first and second biopsies for CT patients revealed that 1 case classified as stage F4 did not show any change in the stage, 2 as stages F3 and F0 changed to F4 and F1, respectively. In contrast, analysis of the second liver biopsies of the CR group showed that 6 cases were classified as F4 (30%), 2 as F3 (10%), 3 as F1 (15%), and 9 as stage F0 (45%). Thus, in this group, 11 cases showed improvement after IFN therapy while 9 cases showed no change and none showed worsening of the staging score. Improvement in the stage of fibrosis according to the staging score in patients of the CR group was 2 of 8 in F4 (25%), 3 of 4 in F3 (75%), 1 of 1 in F2 (100%), 5 of 5 in F1 (100%). The staging score progressed in 4 of the 5 CT cases while the remaining case showed no change. With regard to the 8 cases with CR who had liver cirrhosis (F4) at the first biopsy, only 2 showed improvement while the remaining 6 showed no changes in the classical fibrosis staging score. The rate of yearly change in the staging score (progression of fibrosis and regression) was calculated as the change in fibrosis stage divided by the time between biopsies. The progression rate in the CT group was +0.22/year while the regression rate in the CR group was -0.36/year.
Extent of fibrosis by computed image analysis
In the CR group, the relative area of fibrosis in the first biopsy samples ranged from 1.0 to 28.9% (mean, 7.2±1.5%). In the second biopsy samples, the corresponding area was significantly smaller than in the first biopsy (p=0.0001), ranging from 0.2 to 8.4% (mean, 2.7±0.5%, Table 2 ). In the 8 patients with liver cirrhosis in the CR group, the corresponding area of the first and the second biopsy was 12.4± 2.8% and 4.8±0.8%, respectively, and they were significantly regressed (p=0.0125) (Fig. 2) was 3.7±0.8% and 1.3±0.3%, respectively, and they were also significantly regressed (p=0.0072) (Fig.2) . Comparison of the relative area of fibrosis in the paired biopsies showed that fibrosis regressed in 19 cases and only one case showed progression of fibrosis (Fig. 2) .
In the CT group, the relative area of fibrosis in the first biopsy ranged from 0.6 to 24.5% (mean, 8.4±4.3%). In the second biopsy samples, the corresponding area was significantly larger than in the first biopsy and ranged from 3. gression of fibrosis.
In 9 cases of the CR group who did not show any improvement in the staging score, the relative area of fibrosis was significantly regressed in the whole group from 10.1± 2.8% in the first biopsy to 4.0±0.8% in the second one (p=0.0077). In the 9 patients with liver cirrhosis (stage F4), only 2 cases showed improvement of the staging score while the other 6 showed no changes. However, quantification of the relative area of fibrosis by computerized image analysis indicated that all cases showed significant regression of fibrosis from 12.4±2.8 to 4.8±0.8% (p=0.0125) (Fig. 2 and Table 2 ).
In Figs. 3, 4 and 5, we present three representative cases that showed apparent decrease of liver fibrosis before and after IFN treatment. They were all evaluated to be F4 by the classical fibrosis staging score system. But the relative area of fibrosis was obviously decreased. Figure 6 shows changes in the rate of fibrosis, i.e., the ratio of the difference between the relative area of fibrosis in the second biopsy specimen to that in the first sample. The percent change was less than 100% in the CR group, indicating that liver fibrosis did not progress but rather decreased between the two biopsies. In contrast, percent change in the CT group ranged from 120 to 605%. The mean change in the rate of fibrosis during the period between the first and second biopsies in the CT group (267.8±89.5%) was significantly different from that of the CR group (-53.1±6.9%, p<0.0001, Fig. 6 ).
Extent of regression or progression of liver fibrosis
Discussion
Antiviral therapy against HCV infection has been widely used for chronic liver diseases caused by HCV infection. Termination of the necro-inflammatory reaction after clearance of the underlying etiological factor(s) might result in improvement of liver fibrosis (1, (9) (10) (11) (12) (13) (14) . In particular, IFN treatment has been clinically used for infected patients for over ten years in Japan. In a recent report, some of the CR patients showed apparently decreased liver fibrosis after IFN treatment for HCV infection. Such cases showed dense accumulation of collagen fibers and narrowing of the region around the portal area and disappearance of bridging fibrosis with hepatic lobule deformation 3 to 5 years after treatment (4) . Similarly, several studies demonstrated that liver fibrosis categorized as stage F3 or even F4, can improve more than 3 years after clearance of HCV (2) . In this study, we demonstrated that quantification of liver fibrosis after resolving HCV-related hepatopathy was performed by digital image analysis. Our results showed that in 19 out of 20 patients who showed viral eradication, the relative area of liver fibrosis decreased after IFN therapy, while no such change was noted in patients who did not receive such treatment (CT group).
The classical fibrosis staging score system (7) and Knodell's HAI score (histological activity index) are widely used for measuring and evaluating the histopathological stage of liver fibrosis, due to their high reproducibility and convenience (8) . The staging score of fibrosis in liver disease is determined and accepted by most hepatologists and pathologists, however, this classification system does not allow quantitative evaluation or comparison of the extent and change of fibrosis (7) . On the other hand, Knodell's HAI scoring system is not very sensitive for evaluating subtle changes in liver fibrosis such as those expected after IFN therapy (15) (16) (17) . The classical fibrosis staging score is based on evaluation of the distribution and extent of fibrosis in the liver biopsy specimen, however, the anticipated problem is that the criteria might vary depending on examiner and the size of the obtained tissue. According to the classical fibrosis staging score system, staging in chronic liver hepatitis is classified into four stages, from F0 to F3 while cirrhosis is represented by stage F4. Unfortunately, there is no sensitive evaluation method for the evaluation of minimal fibrosis. Moreover, the volume of fibrosis could be quite different even in samples scored as F4 stage. Thus, there is no sensitive and quantitative evaluation method for the extent of fibrosis in liver cirrhosis. Even if chronic hepatitis has already progressed to cirrhosis, it is possible to reduce the risk of hepatocarcinogenesis and improve prognosis if fibrosis could be regressed by eradicating the causative virus by IFN or other anti-viral drugs (18) (19) (20) (21) (22) .
Our quantitative evaluation is very useful for evaluating subtle changes that cannot be evaluated by the staging score system especially in the CR group. We presented confirmation of the regression of liver fibrosis in patients treated for chronic liver disease and eradicated the causative virus even for liver cirrhosis (F4) by using computed image analysis. 
